Guerbet SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Sadif Analytics Prime
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Guerbet SA reaffirms FY 2014 revenue guidance
Guerbet SA:Sees FY 2014 revenue of 412 mln euros, plus or minus 2 pct.Sees operating margin on reported sales to 9%-10% (compared to initial guidance of 8%-9%).FY 2014 sales 408.80 mln euros - Thomson Reuters I/B/E/S Estimates.
Latest Developments for Guerbet SA
- Guerbet SA reaffirms FY 2014 revenue guidance
- Guerbet SA announces ANSM approval of Lipiodol Ultra-Fluid for visualization, localization and vectorization of hepatocellular carcinoma during trans-arterial chemoembolization
- Guerbet SA announces FDA approves Lipiodol (Ethiodized Oil) injection for imaging of tumors in adults
- Guerbet SA proposes FY 2013 dividend and issues FY 2014 financial guidance
- Share this
- Digg this